Chimeric antigen receptor (CAR)-T cells have shown efficacy in patients with B cell malignancies. Yet their application for solid tumors has challenges that include limited cancer-specific targets and non-persistence of adoptively transferred CAR-T cells. Here we introduce the developmentally regulated tight junction protein claudin 6 (CLDN6) as a CAR target in solid tumors, and a strategy to overcome inefficient CAR-T cell stimulation in vivo. We demonstrate that a nanoparticulate RNA vaccine, designed for body-wide delivery of the CAR antigen into lymphoid compartments, stimulates adoptively transferred CAR-T cells. Presentation of the natively folded target on resident dendritic cells promotes cognate and selective expansion of CAR-T cells. Improved engraftment of CAR-T cells and regression of large tumors in difficult-to-treat mouse models was achieved at sub-therapeutic CAR-T cell doses.
Author Info: (1) Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech Cell & Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, An der Goldgrube 12, 55131 Main
Author Info: (1) Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech Cell & Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, An der Goldgrube 12, 55131 Mainz, Germany. (2) Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech Cell & Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, An der Goldgrube 12, 55131 Mainz, Germany. (3) Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech Cell & Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, An der Goldgrube 12, 55131 Mainz, Germany. (4) Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech Cell & Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, An der Goldgrube 12, 55131 Mainz, Germany. (5) Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech Cell & Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, An der Goldgrube 12, 55131 Mainz, Germany. (6) Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech Cell & Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, An der Goldgrube 12, 55131 Mainz, Germany. (7) Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech Cell & Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, An der Goldgrube 12, 55131 Mainz, Germany. (8) Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech Cell & Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, An der Goldgrube 12, 55131 Mainz, Germany. (9) Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech Cell & Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, An der Goldgrube 12, 55131 Mainz, Germany. (10) Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech Cell & Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, An der Goldgrube 12, 55131 Mainz, Germany. (11) Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech Cell & Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, An der Goldgrube 12, 55131 Mainz, Germany. (12) TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University GmbH, Freiligrathstr. 12, 55131 Mainz, Germany. (13) TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University GmbH, Freiligrathstr. 12, 55131 Mainz, Germany. (14) TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University GmbH, Freiligrathstr. 12, 55131 Mainz, Germany. (15) Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech Cell & Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, An der Goldgrube 12, 55131 Mainz, Germany. (16) Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech Cell & Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, An der Goldgrube 12, 55131 Mainz, Germany. (17) Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech Cell & Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, An der Goldgrube 12, 55131 Mainz, Germany. (18) Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech Cell & Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, An der Goldgrube 12, 55131 Mainz, Germany. (19) Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech Cell & Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, An der Goldgrube 12, 55131 Mainz, Germany. (20) TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University GmbH, Freiligrathstr. 12, 55131 Mainz, Germany. (21) Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech Cell & Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, An der Goldgrube 12, 55131 Mainz, Germany. (22) Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech Cell & Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, An der Goldgrube 12, 55131 Mainz, Germany. (23) Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech Cell & Gene Therapies GmbH, BioNTech Innovative Manufacturing Services GmbH, An der Goldgrube 12, 55131 Mainz, Germany. ugur.sahin@biontech.de. TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University GmbH, Freiligrathstr. 12, 55131 Mainz, Germany.